| Published Application/Species/Sample/Dilution | Reference |
|---|
- western blot; human; 1:500; fig 3
| Iimori M, Watanabe S, Kiyonari S, Matsuoka K, Sakasai R, Saeki H, et al. Phosphorylation of EB2 by Aurora B and CDK1 ensures mitotic progression and genome stability. Nat Commun. 2016;7:11117 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:100; fig 7
| Piazzolla D, Palla A, Pantoja C, Canamero M, de Castro I, Ortega S, et al. Lineage-restricted function of the pluripotency factor NANOG in stratified epithelia. Nat Commun. 2014;5:4226 pubmed publisher |
| Kao Y, Wu C, Wu S, Lan S, Liu H, Tseng Y. Arsenic treatment increase Aurora-A overexpression through E2F1 activation in bladder cells. BMC Cancer. 2017;17:277 pubmed publisher |
| Goos J, Coupe V, Diosdado B, Delis van Diemen P, Karga C, Belien J, et al. Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis. Br J Cancer. 2013;109:2445-52 pubmed publisher |
| Sillars Hardebol A, Carvalho B, de Wit M, Postma C, Delis van Diemen P, Mongera S, et al. Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression. Tumour Biol. 2010;31:89-96 pubmed publisher |
| Lee Y, Choi E, Kim M, Park P, Park N, Lee H. BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers. Br J Cancer. 2009;101:504-10 pubmed publisher |
| Loddo M, Kingsbury S, Rashid M, Proctor I, Holt C, Young J, et al. Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. Br J Cancer. 2009;100:959-70 pubmed publisher |
